Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, and Cutaneous Melanoma Detection and Management.
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status
Redirecting resistance evolution in <i> BRAF <sup>V600</sup> </i> melanoma by inhibition of the peroxiredoxin-thioredoxin system
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma
PTHrP-induced hypercalcemic psychosyndrome under combined anti-PD-L1 and anti-EGFR inhibition in penile squamous cell carcinoma – A case report
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies
Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma
KDM5B predicts temozolomide-resistant subclones in glioblastoma
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Prognostic factors in the primary care of patients with Merkel cell carcinoma: A monocentric cohort study of 108 patients from a tertiary referral centre
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
MCU controls melanoma progression through a redox‐controlled phenotype switch
Persister state-directed transitioning and vulnerability in melanoma
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF<sup>V600</sup></i>-positive melanoma: Interim analysis of the ImmunoCobiVem study.
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases